Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
The present invention refers to a pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients.
1. A method for improving glucose tolerance in a diabetes type 2 patient in need thereof, comprising administering to said patient a therapeutically effective amount of the pharmaceutical combination comprising (a) desPro 36 Exendin-4(1-39)-Lys 6 -NH 2 or/and a pharmaceutically acceptable salt thereof, and (b) metformin or/and a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the patient to be treated is younger than 50 years and has a 2 hour postprandial plasma glucose concentration of at least 14 mmol/L.
2. The method of claim 1 , wherein said patient is obese.
3. The method of claim 1 , wherein said patient has a body mass index of at least 30 kg/m 2 .
4. The method of claim 1 , wherein said patient is an adult subject.
5. The method of claim 1 , wherein said patient does not receive an antidiabetic treatment.
6. The method of claim 1 , wherein diabetes mellitus type 2 has been diagnosed in said patient at least 1 year or at least 2 years before onset of therapy.
7. The method of claim 1 , wherein said patient has a HbA 1c value of about 7 to about 10%.
8. The method of claim 1 , wherein said patient has a fasting plasma glucose concentration of at least 8 mmol/L.
9. The method of claim 1 , wherein said patient has a glucose excursion of at least 2 mmol/L, at least 3 mmol/L, at least 4 mmol/L or at least 5 mmol/L, wherein the glucose excursion is the difference of the 2 hour postprandial plasma glucose concentration and plasma glucose concentration 30 minutes prior to a meal test.